Top

Published in:

Open Access 01-08-2021 | Metastasis | Original Article

Long-term follow-up of children with neuroblastoma receiving radiotherapy to metastatic lesions within the German Neuroblastoma Trials NB97 and NB 2004

Authors: Dr. med. Danny Jazmati, Sarina Butzer, Barbara Hero, Jerome Doyen, Dalia Ahmad Khalil, Theresa Steinmeier, Stefanie Schulze Schleithoff, Angelika Eggert, Thorsten Simon, Beate Timmermann

Published in: Strahlentherapie und Onkologie | Issue 8/2021

Abstract

Purpose

Neuroblastoma (NB) is the most common extracranial solid malignancy during childhood. Despite a multimodal treatment approach, the prognosis of patients with metastatic NB is not satisfactory. Although radiotherapy (RT) has become an integral part of treatment of the primary tumor, the role of RT in osteomedullary lesions is not well defined. A retrospective analysis was conducted to evaluate the impact of RT for metastatic sites in children with high-risk NB.

Methods

All patients with stage 4 NB from the prospective, multicenter NB trials NB97 and NB2004 who received RT to metastatic sites during frontline treatment were included in this retrospective analysis.

Results

A total of 18 children were irradiated with a median dose of 36 Gray (Gy; range 20–45 Gy) to one or more (range 1–3) osteomedullary metastases with or without concomitant RT to the primary tumor site. The median follow-up time was 149 months (range 55–220) in survivors. At 5 years, local relapse-free survival (LRFS) at irradiated metastatic sites and metastases-free survival (MFS) at distant, non-irradiated site rates were 51.4 and 39.9%, respectively. The estimated overall survival (OS) rate at 5 years was 49.4%. No high-grade acute or late toxicity and no secondary malignancy was reported.

Conclusion

RT to metastases is feasible for patients with stage 4 NB. However, an impact of RT to residual metastatic sites on outcome was not found. Studies with larger cohorts or prospective trials would be desirable in order to elucidate the role of RT for metastases.

Pudela C, Balyasny S, Applebaum MA (2020) Nervous system: embryonal tumors: neuroblastoma. Atlas Genet Cytogenet Oncol Haematol 24:284–290. https://doi.org/10.4267/2042/70771CrossRefPubMedPubMedCentral

Simon T, Hero B, Faldum A et al (2011) Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 11:21. https://doi.org/10.1186/1471-2407-11-21CrossRefPubMedPubMedCentral

Valteau-Couanet D, Le Deley M‑C, Bergeron C et al (2014) Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. Pediatr Blood Cancer 61:977–981. https://doi.org/10.1002/pbc.24713CrossRefPubMed

Tas ML, Reedijk AMJ, Karim-Kos HE et al (2020) Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma. Eur J Cancer 124:47–55. https://doi.org/10.1016/j.ejca.2019.09.025CrossRefPubMed

DuBois SG, Kalika Y, Lukens JN et al (1999) Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21:181–189CrossRef

Morgenstern DA, London WB, Stephens D et al (2016) Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer 65:1–10. https://doi.org/10.1016/j.ejca.2016.06.005CrossRefPubMed

Zhao Q, Liu Y, Zhang Y et al (2020) Role and toxicity of radiation therapy in neuroblastoma patients: a literature review. Crit Rev Oncol Hematol 149:102924. https://doi.org/10.1016/j.critrevonc.2020.102924CrossRefPubMed

Casey DL, Pitter KL, Kushner BH et al (2018) Radiation therapy to sites of metastatic disease as part of consolidation in high-risk neuroblastoma: can long-term control be achieved? Int J Radiat Oncol Biol Phys 100:1204–1209. https://doi.org/10.1016/j.ijrobp.2018.01.008CrossRefPubMedPubMedCentral

Mazloom A, Louis CU, Nuchtern J et al (2014) Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 90:858–862. https://doi.org/10.1016/j.ijrobp.2014.07.019CrossRefPubMedPubMedCentral

10.

Polishchuk AL, Li R, Hill-Kayser C et al (2014) Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 89:839–845. https://doi.org/10.1016/j.ijrobp.2014.04.004CrossRefPubMed

11.

Kushner BH, Wolden S, LaQuaglia MP et al (2001) Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol 19:2821–2828. https://doi.org/10.1200/JCO.2001.19.11.2821CrossRefPubMed

12.

Liu KX, Naranjo A, Zhang FF et al (2020) Prospective evaluation of radiation dose escalation in patients with high-risk neuroblastoma and gross residual disease after surgery: a report from the children’s oncology group ANBL0532 study. J Clin Oncol. https://doi.org/10.1200/JCO.19.03316CrossRefPubMedPubMedCentral

13.

Berthold F, Boos J, Burdach S et al (2005) Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 6:649–658. https://doi.org/10.1016/S1470-2045(05)70291-6CrossRefPubMed

14.

Berthold F, Faldum A, Ernst A et al (2020) Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. Ann Oncol 31:422–429. https://doi.org/10.1016/j.annonc.2019.11.011CrossRefPubMed

15.

Schmidt M, Simon T, Hero B et al (2006) Is there a benefit of 131 I‑MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin 45:145–151 (quiz N39–40)CrossRef

16.

Simon T, Hero B, Bongartz R et al (2006) Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children 〉1 year with residual local disease. Strahlenther Onkol 182:389–394. https://doi.org/10.1007/s00066-006-1498-8CrossRefPubMed

17.

Kandula S, Prabhu RS, Nanda R et al (2015) Outcomes after radiation therapy to metastatic sites in patients with stage 4 neuroblastoma. J Pediatr Hematol Oncol 37:175–180. https://doi.org/10.1097/MPH.0000000000000264CrossRefPubMedPubMedCentral

18.

Créhange G, Soussan M, Gensanne D et al (2020) Interest of positron-emission tomography and magnetic resonance imaging for radiotherapy planning and control. Cancer Radiother J Soc Francaise 24:398–402. https://doi.org/10.1016/j.canrad.2020.02.010CrossRef

19.

Li H‑F, Mao H‑J, Zhao L et al (2020) The diagnostic accuracy of PET(CT) in patients with neuroblastoma: a meta-analysis and systematic review. J Comput Assist Tomogr 44:111–117. https://doi.org/10.1097/RCT.0000000000000973CrossRefPubMed

20.

Samołyk-Kogaczewska N, Sierko E, Zuzda K et al (2019) PET/MRI-guided GTV delineation during radiotherapy planning in patients with squamous cell carcinoma of the tongue. Strahlenther Onkol 195:780–791. https://doi.org/10.1007/s00066-019-01480-3CrossRefPubMedPubMedCentral

21.

Jouin A, Helfre S, Bolle S et al (2019) Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: the French experience. Strahlenther Onkol 195:504–516. https://doi.org/10.1007/s00066-019-01461-6CrossRefPubMed

22.

Meroni S, Cavatorta C, Barra S et al (2019) A dedicated cloud system for real-time upfront quality assurance in pediatric radiation therapy. Strahlenther Onkol 195:843–850. https://doi.org/10.1007/s00066-019-01469-yCrossRefPubMed

Title: Long-term follow-up of children with neuroblastoma receiving radiotherapy to metastatic lesions within the German Neuroblastoma Trials NB97 and NB 2004
Authors: Dr. med. Danny Jazmati
Sarina Butzer
Barbara Hero
Jerome Doyen
Dalia Ahmad Khalil
Theresa Steinmeier
Stefanie Schulze Schleithoff
Angelika Eggert
Thorsten Simon
Beate Timmermann
Publication date: 01-08-2021
Publisher: Springer Berlin Heidelberg
Keywords: Metastasis
Neuroblastoma
Neuroblastoma
Radiotherapy
Published in: Strahlentherapie und Onkologie / Issue 8/2021
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-020-01718-5

At a glance: The STEP trials

Springer Medicine

Long-term follow-up of children with neuroblastoma receiving radiotherapy to metastatic lesions within the German Neuroblastoma Trials NB97 and NB 2004

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2021

Effektivität einer sequenziellen versus einer simultanen Radiochemotherapie oder alleinigen Radiotherapie bei der adjuvanten Behandlung des Zervixkarzinoms nach Hysterektomie

Peer review analysis in the field of radiation oncology: results from a web-based survey of the Young DEGRO working group

The risk of late effects following pediatric and adult radiotherapy regimens in Hodgkin lymphoma

Pattern of relapse in pediatric localized extremity rhabdomyosarcomas correlated with locoregional therapies administered

Normo- versus hypofraktionierte Bestrahlung nach plastischer Brustrekonstruktion: Toxizitätsanalyse einer retrospektiven Kohortenstudie

Morbidität und Letalität einer COVID-19-Erkrankung bei Tumorpatienten: eine gematchte Kohortenstudie